Cargando…

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)

Detalles Bibliográficos
Autores principales:	Stegelmann, Frank, Teichmann, Lino L., Heidel, Florian H., Crodel, Carl C., Ernst, Thomas, Kreil, Sebastian, Reiter, Andreas, Otten, Sara, Schauer, Stefanie, Körber, Ruth-Miriam, Kricheldorf, Kim, Isfort, Susanne, Döhner, Hartmut, Brümmendorf, Tim H., Griesshammer, Martin, Döhner, Konstanze, Koschmieder, Steffen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079540/ https://www.ncbi.nlm.nih.gov/pubmed/36828867 http://dx.doi.org/10.1038/s41375-023-01837-9

Ejemplares similares

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021)

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
por: Koschmieder, Steffen, et al.
Publicado: (2022)

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2020)

Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2021)

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
por: Gecht, Judith, et al.
Publicado: (2021)

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
por: Crodel, Carl C., et al.
Publicado: (2020)

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
por: Manz, Kirsi, et al.
Publicado: (2023)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
por: Stegelmann, F., et al.
Publicado: (2022)

Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms
por: Kalmer, Milena, et al.
Publicado: (2022)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
por: Jutzi, Jonas S., et al.
Publicado: (2013)

Renal biopsy cases in myeloproliferative neoplasms (MPN)
por: Fujita, Kumi, et al.
Publicado: (2013)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
por: Wille, Kai, et al.
Publicado: (2023)

Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells
por: Lubberich, Richard K., et al.
Publicado: (2018)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN
por: Tillmann, Stefan, et al.
Publicado: (2021)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany
por: Schmidt, Andreas, et al.
Publicado: (2023)

Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
por: Bhuria, Vikas, et al.
Publicado: (2022)

Clinicohematological Study of Thrombocytosis in Children
por: Subramaniam, Nathiya, et al.
Publicado: (2014)

Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms
por: Ha, Jung-Sook, et al.
Publicado: (2012)

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
por: Harrison, Claire N., et al.
Publicado: (2017)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Casetti, I. C., et al.
Publicado: (2022)

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
por: Birgegård, Gunnar
Publicado: (2016)

Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm
por: Molitor, David C. A., et al.
Publicado: (2020)

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing
por: Kirschner, Martin M. J., et al.
Publicado: (2015)

Methylation of SOCS3 in Myeloproliferative Neoplasms and Secondary Erythrocytosis/Thrombocythemia
por: Torun, Deniz, et al.
Publicado: (2013)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN)
por: Price, Gregory L., et al.
Publicado: (2014)

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)

EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper
por: Macintyre, Elizabeth, et al.
Publicado: (2020)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey
por: Byun, Ja Min, et al.
Publicado: (2022)

Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
por: Anwar, Nida, et al.
Publicado: (2017)

Surgical Complications in Myeloproliferative Neoplasm Patient with Essential Thrombocythemia: A Case Report
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8d6oh2rnmakk2pejbr8oat6a6m